SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Primary Systemic Amyloidosis. According to GlobalData, Phase I drugs for Primary Systemic Amyloidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SG-2501 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SG-2501 overview

SG-2501 is under development for the treatment of hematological tumors like multiple myeloma, chronic lymphocytic leukemia, primary systemic amyloidosis, Waldenstrom macroglobulinemia, b-cell Hodgkin lymphoma, non-Hodgkin lymphoma, relapsed multiple myeloma, refractory multiple myeloma and diffuse large b-cell lymphoma. The drug candidate is a bi-specific monoclonal antibody and acts by targeting cell surface antigen CD38/CD47. The drug candidate is administered through intravenous route.

Hangzhou Sumgen Biotech overview

Hangzhou Sumgen Biotech, formerly Hangzhou Shangjian Biotechnology Co Ltd, is a drug development company specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnostics. The company is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of SG-2501’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.